Identification of a novel immune landscape signature as effective diagnostic markers related to immune cell infiltration in diabetic nephropathy.
CCR2
CX3CR1
SELP
diabetic nephropathy
diagnose biomarker
immune cells infiltration
renal tubulointerstitial injury
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
12
2022
accepted:
22
02
2023
medline:
28
3
2023
entrez:
27
3
2023
pubmed:
28
3
2023
Statut:
epublish
Résumé
The study aimed to identify core biomarkers related to diagnosis and immune microenvironment regulation and explore the immune molecular mechanism of diabetic nephropathy (DN) through bioinformatics analysis. GSE30529, GSE99325, and GSE104954 were merged with removing batch effects, and different expression genes (DEGs) were screened at a criterion |log2FC| >0.5 and adjusted P <0.05. KEGG, GO, and GSEA analyses were performed. Hub genes were screened by conducting PPI networks and calculating node genes using five algorithms with CytoHubba, followed by LASSO and ROC analysis to accurately identify diagnostic biomarkers. In addition, two different GEO datasets, GSE175759 and GSE47184, and an experiment cohort with 30 controls and 40 DN patients detected by IHC, were used to validate the biomarkers. Moreover, ssGSEA was performed to analyze the immune microenvironment in DN. Wilcoxon test and LASSO regression were used to determine the core immune signatures. The correlation between biomarkers and crucial immune signatures was calculated by Spearman analysis. Finally, cMap was used to explore potential drugs treating renal tubule injury in DN patients. A total of 509 DEGs, including 338 upregulated and 171 downregulated genes, were screened out. "chemokine signaling pathway" and "cell adhesion molecules" were enriched in both GSEA and KEGG analysis. CCR2, CX3CR1, and SELP, especially for the combination model of the three genes, were identified as core biomarkers with high diagnostic capabilities with striking AUC, sensitivity, and specificity in both merged and validated datasets and IHC validation. Immune infiltration analysis showed a notable infiltration advantage for APC co-stimulation, CD8+ T cells, checkpoint, cytolytic activity, macrophages, MHC class I, and parainflammation in the DN group. In addition, the correlation analysis showed that CCR2, CX3CR1, and SELP were strongly and positively correlated with checkpoint, cytolytic activity, macrophages, MHC class I, and parainflammation in the DN group. Finally, dilazep was screened out as an underlying compound for DN analyzed by CMap. CCR2, CX3CR1, and SELP are underlying diagnostic biomarkers for DN, especially in their combination. APC co-stimulation, CD8+ T cells, checkpoint, cytolytic activity, macrophages, MHC class I, and parainflammation may participate in the occurrence and development of DN. At last, dilazep may be a promising drug for treating DN.
Sections du résumé
Background
The study aimed to identify core biomarkers related to diagnosis and immune microenvironment regulation and explore the immune molecular mechanism of diabetic nephropathy (DN) through bioinformatics analysis.
Methods
GSE30529, GSE99325, and GSE104954 were merged with removing batch effects, and different expression genes (DEGs) were screened at a criterion |log2FC| >0.5 and adjusted P <0.05. KEGG, GO, and GSEA analyses were performed. Hub genes were screened by conducting PPI networks and calculating node genes using five algorithms with CytoHubba, followed by LASSO and ROC analysis to accurately identify diagnostic biomarkers. In addition, two different GEO datasets, GSE175759 and GSE47184, and an experiment cohort with 30 controls and 40 DN patients detected by IHC, were used to validate the biomarkers. Moreover, ssGSEA was performed to analyze the immune microenvironment in DN. Wilcoxon test and LASSO regression were used to determine the core immune signatures. The correlation between biomarkers and crucial immune signatures was calculated by Spearman analysis. Finally, cMap was used to explore potential drugs treating renal tubule injury in DN patients.
Results
A total of 509 DEGs, including 338 upregulated and 171 downregulated genes, were screened out. "chemokine signaling pathway" and "cell adhesion molecules" were enriched in both GSEA and KEGG analysis. CCR2, CX3CR1, and SELP, especially for the combination model of the three genes, were identified as core biomarkers with high diagnostic capabilities with striking AUC, sensitivity, and specificity in both merged and validated datasets and IHC validation. Immune infiltration analysis showed a notable infiltration advantage for APC co-stimulation, CD8+ T cells, checkpoint, cytolytic activity, macrophages, MHC class I, and parainflammation in the DN group. In addition, the correlation analysis showed that CCR2, CX3CR1, and SELP were strongly and positively correlated with checkpoint, cytolytic activity, macrophages, MHC class I, and parainflammation in the DN group. Finally, dilazep was screened out as an underlying compound for DN analyzed by CMap.
Conclusions
CCR2, CX3CR1, and SELP are underlying diagnostic biomarkers for DN, especially in their combination. APC co-stimulation, CD8+ T cells, checkpoint, cytolytic activity, macrophages, MHC class I, and parainflammation may participate in the occurrence and development of DN. At last, dilazep may be a promising drug for treating DN.
Identifiants
pubmed: 36969169
doi: 10.3389/fimmu.2023.1113212
pmc: PMC10030848
doi:
Substances chimiques
Dilazep
F8KLC2BD5Z
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1113212Informations de copyright
Copyright © 2023 Zhou, Mu, Yang and Shi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Kidney Int. 2010 Nov;78(9):883-94
pubmed: 20686445
Cytokine. 2012 Jan;57(1):127-9
pubmed: 22088599
Nephrol Dial Transplant. 2020 Feb 1;35(2):227-239
pubmed: 30597038
Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F716-F731
pubmed: 27558558
Sci Rep. 2017 Jun 2;7(1):2684
pubmed: 28577020
Cytokine. 2005 Aug 7;31(3):180-90
pubmed: 15975818
Front Immunol. 2021 Aug 13;12:726747
pubmed: 34484236
BMB Rep. 2010 Mar;43(3):188-92
pubmed: 20356459
Am J Physiol Renal Physiol. 2011 Dec;301(6):F1358-66
pubmed: 21880831
Biomed Res Int. 2022 May 10;2022:9554658
pubmed: 35592524
J Nephrol. 2017 Dec;30(6):701-717
pubmed: 28840540
Nephron Exp Nephrol. 2004;97(1):e17-25
pubmed: 15153757
Tohoku J Exp Med. 2005 Jun;206(2):163-71
pubmed: 15888973
Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F273-F281
pubmed: 28356293
Endocr Metab Immune Disord Drug Targets. 2019;19(8):1157-1164
pubmed: 30806329
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Ann Transl Med. 2020 Nov;8(21):1427
pubmed: 33313172
Nihon Jinzo Gakkai Shi. 1993 Apr;35(4):329-35
pubmed: 8341008
Biomed Pharmacother. 2018 Nov;107:1115-1118
pubmed: 30257323
Front Oncol. 2021 Oct 25;11:758856
pubmed: 34760705
Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96
pubmed: 26268910
Diabetes Obes Metab. 2019 Mar;21(3):575-583
pubmed: 30311395
J Clin Invest. 2003 Feb;111(4):515-27
pubmed: 12588890
Exp Diabetes Res. 2011;2011:514738
pubmed: 22028700
J Atheroscler Thromb. 2011;18(11):958-65
pubmed: 21873805
Diabetes Metab. 2014 Dec;40(6):459-65
pubmed: 25303803
Nihon Jinzo Gakkai Shi. 1995 Nov;37(11):644-8
pubmed: 8583701
Am J Kidney Dis. 1993 May;21(5):480-5
pubmed: 8488815
Nephrol Dial Transplant. 2012 Aug;27(8):3049-56
pubmed: 22734110
Rev Assoc Med Bras (1992). 2018 Jan;64(1):85-92
pubmed: 29561946
Dis Markers. 2014;2014:493736
pubmed: 24876663
Kidney Blood Press Res. 2021;46(3):275-285
pubmed: 33887734
J Autoimmun. 2009 Mar;32(2):85-93
pubmed: 19200691
Diabetes Care. 2000 Aug;23(8):1168-71
pubmed: 10937516
Curr Opin Pharmacol. 2013 Aug;13(4):602-12
pubmed: 23721739
Biomed Res Int. 2015;2015:301627
pubmed: 26345532
Curr Pharm Des. 2010;16(37):4113-8
pubmed: 21247396
Diabetes Metab Res Rev. 2022 Sep;38(6):e3556
pubmed: 35708187
Ren Fail. 2022 Dec;44(1):862-880
pubmed: 35611435
Kidney Int. 2002 Aug;62(2):488-95
pubmed: 12110009
Front Immunol. 2022 Aug 15;13:958790
pubmed: 36045667
FASEB J. 2022 Sep;36(9):e22501
pubmed: 35971776
Int J Biol Macromol. 2016 Oct;91:233-40
pubmed: 27234491
Curr Gene Ther. 2017;17(6):442-452
pubmed: 29446734
Ther Adv Endocrinol Metab. 2019 Dec 02;10:2042018819891110
pubmed: 31832131
Nephrology (Carlton). 2006 Jun;11(3):226-31
pubmed: 16756636
Endocr Metab Immune Disord Drug Targets. 2023;23(3):294-303
pubmed: 35713142
Nat Rev Nephrol. 2011 Jun;7(6):327-40
pubmed: 21537349
J Am Soc Nephrol. 2005 Jun;16(6):1711-22
pubmed: 15857924
Diabetologia. 1998 Feb;41(2):185-92
pubmed: 9498652
Nephron. 2000 Jul;85(3):281-2
pubmed: 10867547
Lasers Surg Med. 2022 Oct;54(8):1167-1176
pubmed: 35916125
Diabetologia. 2007 Feb;50(2):471-80
pubmed: 17160673
Mediators Inflamm. 2018 Aug 9;2018:7659243
pubmed: 30158836
J Cell Physiol. 2019 Sep;234(9):16447-16462
pubmed: 30761531
Int J Physiol Pathophysiol Pharmacol. 2018 Mar 10;10(1):29-38
pubmed: 29593848
Ren Fail. 2022 Dec;44(1):293-303
pubmed: 35166173
Am J Physiol Renal Physiol. 2008 Apr;294(4):F697-701
pubmed: 18272603
Diabetes Metab Res Rev. 2014 Nov;30(8):736-41
pubmed: 24687388
Transplant Proc. 2012 May;44(4):1026-8
pubmed: 22564616
J Cell Mol Med. 2020 May;24(10):5817-5831
pubmed: 32283569
Kidney Int. 2000 Oct;58(4):1492-9
pubmed: 11012884
Diabetologia. 2013 Jul;56(7):1661-9
pubmed: 23604552
Neural Regen Res. 2022 Oct;17(10):2153-2156
pubmed: 35259822
J Diabetes Res. 2021 May 24;2021:5546199
pubmed: 34124269
Curr Vasc Pharmacol. 2010 Nov;8(6):849-60
pubmed: 20180766
Front Oncol. 2022 Apr 01;12:831506
pubmed: 35433476
Ren Fail. 2022 Dec;44(1):1309-1318
pubmed: 35938702
Clin Lab. 2017 Feb 1;63(2):241-247
pubmed: 28182344
Clin Sci (Lond). 2017 Jul 31;131(16):2183-2199
pubmed: 28760771
Transl Res. 2017 May;183:1-13
pubmed: 28034759
J Diabetes Complications. 2012 Nov-Dec;26(6):546-53
pubmed: 22981148
Cell Tissue Res. 2021 Aug;385(2):335-344
pubmed: 34009468
BMC Nephrol. 2021 Jul 2;22(1):245
pubmed: 34215202
Blood. 2021 Aug 5;138(5):401-416
pubmed: 33895821
Am J Nephrol. 2012;35(2):164-74
pubmed: 22286547
J Clin Lab Anal. 1995;9(6):380-6
pubmed: 8587006
J Am Soc Nephrol. 2006 Feb;17(2):368-77
pubmed: 16394109
Nephrol Dial Transplant. 2017 Aug 01;32(8):1322-1329
pubmed: 27416772
Clin Sci (Lond). 2018 Jun 26;132(12):1297-1314
pubmed: 29760122
Front Cell Dev Biol. 2021 Mar 18;9:606106
pubmed: 33816462
Metabolites. 2022 Nov 23;12(12):
pubmed: 36557204
Clin Exp Pharmacol Physiol. 2007 Oct;34(10):1016-9
pubmed: 17714088
Drugs Exp Clin Res. 2002;28(6):221-7
pubmed: 12776575
Kidney Int. 2011 Jul;80(1):68-78
pubmed: 21508925
Hypertens Res. 2011 Jun;34(6):747-52
pubmed: 21451526
Clin Appl Thromb Hemost. 2007 Oct;13(4):391-7
pubmed: 17911190
Front Oncol. 2021 May 28;11:682932
pubmed: 34123852
Life Sci. 2021 May 01;272:118808
pubmed: 33245967